Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2009. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in beneficial interests in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a regulatory disclosure of a specific share transaction and does not contain financial performance data.
Material Changes
The only material change disclosed is the acquisition of a beneficial interest by Mr. S M Bicknell. He acquired 10 Ordinary shares on April 6, 2009, at a price of £10.42 per share. This transaction resulted from the re-investment of dividends under a Personal Equity Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The document is limited to the notification of the share transaction in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Mr. S M Bicknell acquired 10 Ordinary shares of GlaxoSmithKline plc.
- The transaction occurred on April 6, 2009, via dividend re-investment under a Personal Equity Plan.
- The acquisition price was £10.42 per share.
- The company was advised of this transaction on April 7, 2009.
- This filing does not contain financial results or strategic updates.